Skip to the main content.

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals, "Cellicon Valley" and the "Golden Triangle

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals,

In this third instalment to our cell and gene blog series, author Dave Seaward explains where most ATMP technology is being delivered as well as providing insight into why.

Click here to gain an understanding of why investors believe significant returns will be made from these technologies.
Behind the scenes of 3P innovation's Customer Care team

Behind the scenes of 3P innovation's Customer Care team

Picture of Georgia Lewis-Marston Georgia Lewis-Marston: 17 October 2025

This week, I had the chance to sit down with Paul Beard, Operations Director at 3P innovation, to explore what truly distinguishes our Customer Care...

Read More
Filling syringes with spray-dried powders - the how, the why and the benefits.

Filling syringes with spray-dried powders - the how, the why and the benefits.

David Phasey: 15 October 2025

For many therapy developers, the challenge doesn’t start in manufacturing, it begins much earlier in formulation. Once a promising therapy has...

Read More
What does Annex 1 mean for cryovial filling? Insights from 3P innovation.

What does Annex 1 mean for cryovial filling? Insights from 3P innovation.

Charles Pilato: 6 October 2025

The revision of EU GMP Annex 1 has redefined expectations for sterile manufacturing across the life sciences sector and nowhere is this felt more...

Read More